NL-OMON56690尚未招募不适用
The Role of Type I Interferon in Interstitial Lung Disease - INITIALISE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •In order to be eligible to participate in this study as a patient, a subject
- •must meet all of the
- •following criteria:
- •1.Established diagnosis of:
- •-SAD without ILD (according to the latest ACR-EULAR criteria)
- •-SAD with ILD (according to the latest ACR-EULAR criteria and ILD diagnostics)
- •-IPAF patients (according to latest consensus) [9]
- •-IPF patients (according to latest diagnostics) [11]
- •2.Age >= 18 years
- •3. Providing informed consent after reading patient information.
排除标准
- •A potential subject who meets any of the following criteria will be excluded
- •from participation in this study:
- •1.No established diagnosis of SAD, IPAF or IPF.
- •2.Refusal to participate in the study.
- •3.Insufficient knowledge of the Dutch language.
研究者
相似试验
招募中
不适用
Role and mechanism of type I interferon in the pathogenesis of anti-MDA5 antibody-positive dermatomyositisAnti-MDA5 antibody-positive dermatomyositisJPRN-UMIN000049776Chiba University150
已完成
1 期
Interferon as a Mucosal Adjuvant for Influenza Vaccine Given IntranasallyInfluenzaNCT00436046National Institute of Allergy and Infectious Diseases (NIAID)95
招募中
不适用
Pulmonary involvement (interstitial lung disease of known etiology) in patients with Seropositive and ACPA positive Rheumatoid Arthritis (RA-ILD I and II)Early detection of lung involvement in RAM05.9M05.1J99.0Seropositive rheumatoid arthritis, unspecifiedRheumatoid lung diseaseDRKS00028871Boehringer Ingelheim Pharma GmbH & Co. KG200
已完成
不适用
Study of interstitial lung disease in primary antibody deficiencyD83.9J84.8Common variable immunodeficiency, unspecifiedOther specified interstitial pulmonary diseasesDRKS00000799niversitätsklinikum FreiburgCentrum für Chronische Immundefizienz (CCI)150
进行中（未招募）
1 期
Interleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation: Randomized, controlled study assessing efficacy and safety of Anakinra and RuxolitinibCovid-19 diseaseEUCTR2020-001963-10-FRCentre Hospitalier Intercommunal de Toulon La Seyne-sur-mer54